{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:36Z","timestamp":1790916816623,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":162,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101286","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:41:02Z","timestamp":1781847662000},"page":"101286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Alternative bevacizumab schedule in high-grade gliomas recurrence is associated with reductions in greenhouse gas emissions without loss of clinical efficacy"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7096-2684","authenticated-orcid":false,"given":"Judith","family":"Lego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Larroquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Pedeboscq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien Le","family":"Chanjour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Digue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymeri","family":"Huchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jecko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bronnimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101286_bib0001","series-title":"Climate Change and Health [Internet]","year":"2026"},{"issue":"10419","key":"10.1016\/j.ctarc.2026.101286_bib0002","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(23)01859-7","article-title":"The 2023 report of the lancet countdown on health and climate change: the imperative for a health-centred response in a world facing irreversible harms","volume":"402","author":"Romanello","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101286_bib0003","unstructured":"Intergovernmental Panel on Climate Change (IPCC). Sixth Assessment report (AR6) [Internet]. [cited 2026 Jun 6]. Available from: https:\/\/www.ipcc.ch\/assessment-report\/ar6\/."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101286_bib0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101286_bib0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101286_bib0006","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the treatment of glioblastoma multiforme: a literature review and clinical outcomes","volume":"31","author":"Jezierza\u0144ski","year":"2024","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101286_bib0007","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/cancers11020174","article-title":"Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review","volume":"11","author":"Fabian","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101286_bib0008","doi-asserted-by":"crossref","first-page":"vdaf203","DOI":"10.1093\/noajnl\/vdaf203","article-title":"Relation between tumor treating fields usage rate \u226575% for the first 3 months and progression-free survival in patients with newly diagnosed WHO grade 4 gliomas","volume":"7","author":"Deguchi","year":"2025","journal-title":"Neuro. Oncol. Adv."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101286_bib0009","first-page":"6480","article-title":"Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis","volume":"25","author":"Zhang","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101286_bib0010","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101286_bib0011","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1002\/cncr.25462","article-title":"A phase II trial of single-agent bevacizumab given every 3 weeks for patients with recurrent high-grade gliomas","volume":"116","author":"Raizer","year":"2010","journal-title":"Cancer"},{"issue":"33","key":"10.1016\/j.ctarc.2026.101286_bib0012","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101286_bib0013","first-page":"23","article-title":"Decarbonation at AP-HP: the momentum is set to build","volume":"75","author":"Klinguer","year":"2025","journal-title":"Rev. Prat."},{"key":"10.1016\/j.ctarc.2026.101286_bib0014","unstructured":"ADEME. Base empreinte\u00ae [Internet]. [cited 2025 May 21]. Available from: https:\/\/base-empreinte.ademe.fr\/."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101286_bib0015","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1016\/S2542-5196(24)00245-6","article-title":"Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis","volume":"8","author":"Malmberg","year":"2024","journal-title":"Lancet Planet. Health"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101286_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/jpm10030079","article-title":"Pharmacogenomics, pharmacokinetics and circulating proteins as biomarkers for bevacizumab treatment optimization in patients with cancer: a review","volume":"10","author":"Papachristos","year":"2020","journal-title":"J. Pers. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101286_bib0017","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/WCO.0000000000001320","article-title":"Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials","volume":"37","author":"Fukushima","year":"2024","journal-title":"Curr. Opin. Neurol."},{"issue":"42","key":"10.1016\/j.ctarc.2026.101286_bib0018","doi-asserted-by":"crossref","first-page":"14012","DOI":"10.1021\/acssuschemeng.1c01435","article-title":"Cost\u2013benefit analysis of monoclonal antibody cultivation scenarios in terms of life cycle environmental impact and operating cost","volume":"9","author":"Amasawa","year":"2021","journal-title":"ACS Sustain. Chem. Eng."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101286_bib0019","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/OP.23.00227","article-title":"Alternative trastuzumab dosing schedules are associated with reductions in health care greenhouse gas emissions","volume":"19","author":"Jacobson","year":"2023","journal-title":"JCo Oncol. Pract."},{"key":"10.1016\/j.ctarc.2026.101286_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nbt.2022.01.002","article-title":"Streamlined life cycle assessment of single use technologies in biopharmaceutical manufacture","volume":"68","author":"Budzinski","year":"2022","journal-title":"New Biotechnol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101286_bib0021","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/jctb.5975","article-title":"Environmental sustainability assessment of the manufacturing process of a biological active pharmaceutical ingredient","volume":"94","author":"Renteria Gamiz","year":"2019","journal-title":"J. Chem. Technol. Biotechnol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101286_bib0022","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/btpr.2323","article-title":"Life-cycle and cost of goods assessment of fed-batch and perfusion-based manufacturing processes for mAbs","volume":"32","author":"Bunnak","year":"2016","journal-title":"Biotechnol. Prog."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101286_bib0023","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3747\/co.23.3108","article-title":"Progression pattern and adverse events with bevacizumab in glioblastoma","volume":"23","author":"Mamo","year":"2016","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101286_bib0024","first-page":"428","article-title":"A real-world claims analysis of costs and patterns of care in treated patients with glioblastoma multiforme in the United States","volume":"25","author":"Norden","year":"2019","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101286_bib0025","first-page":"633","article-title":"Dose-dependent efficacy of bevacizumab in recurrent glioblastoma","volume":"161","author":"Melhem","year":"2023","journal-title":"J. Neurooncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101286_bib0026","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101286_bib0027","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41416-020-01255-z","article-title":"Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice","volume":"124","author":"Waller","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101286_bib0028","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpt.3148","article-title":"Model-based dose selection of subcutaneous nivolumab in patients with advanced solid tumors","volume":"115","author":"Zhao","year":"2024","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:59:43Z","timestamp":1790913583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"alternative-id":["S2468294226001978"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101286","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative bevacizumab schedule in high-grade gliomas recurrence is associated with reductions in greenhouse gas emissions without loss of clinical efficacy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101286"}}